<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778154</url>
  </required_header>
  <id_info>
    <org_study_id>2003096</org_study_id>
    <nct_id>NCT00778154</nct_id>
    <nct_alias>NCT00778635</nct_alias>
  </id_info>
  <brief_title>Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate</brief_title>
  <official_title>A Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Long-Term Alendronate or Risedronate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have received the appropriate number of years of alendronate or risedronate
      therapy will be recruited. Each patient will have received baseline BMD measurements
      performed at the spine and the hip by DXA. Each patient will receive tetracycline to label
      the bone and then have a transiliac bone biopsy. One year later teh bone label and biopsy
      procedure will be repeated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in iliac crest bone histomorphometry and bone quality 9microarchitecture and matrix structure in PMO women receiving long term therapy with alendronate or risedronate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare iliac crest bone histomorphometry and bone quality changes after 5 years of more of alendronate or risedronate therapy with 3 years of therapy in PMO women</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">105</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Alendronate 3 to &lt; 5 years</arm_group_label>
    <description>Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate 3 to &lt; 5 Years</arm_group_label>
    <description>Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate ≥ 5 Years</arm_group_label>
    <description>Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate ≥ 5 Years</arm_group_label>
    <description>Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bone biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients from bone research centers who have taken alendronate or risedronate for 3 to 5
        or more years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women at least 5 years postmenopausal

          -  Subjects treated with any combination alendronate 10 mg daily or 70 mg once weekly or
             any combination of risedronate 5mg daily or 35 mg weekly for 3-5 years. Or subjects
             treated with any combination of alendronate 10 mg daily or 70 mg once weekly or any
             combination of risedronate 5mg daily or 35 mg weekly for greater than 5 years.

        Exclusion Criteria:

          -  Presence of metabolic bone disease other than PMO

          -  Use of any medication other than alendronate or risedronate within with in the past 6
             months likely to interfere with skeletal homeostasis.

        Uncontrolled hyperthyroidism. Previous history of malignancy except treated squamous cell
        or basal cell carcinoma of the skin.

          -  Alcohol or drug abuse, current or within the past 5 years.

          -  Allergy to tetracycline, Novocain, or Versed.

          -  Hip anatomy not conducive to transiliac bone biopsy or DXA scan.

          -  Previous bilateral transiliac bone biopsies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen R Marcello, MD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Facility</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

